You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Factor D Inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Trial (TILT-123, Pembrolizumab)

Not yet recruiting
  • Lung Cancer
  • TILT-123
  • Pembrolizumab
  • (no location specified)
Nov 5, 2023

Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score Trial in France

Not yet recruiting
  • Metastatic Renal Cell Carcinoma
  • Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
  • Combination PD-1/PD-L1 ICI + VEGFR-TKI
  • Treatment pause
  • Bayonne, France
  • +24 more
Aug 10, 2022

Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

Active, not recruiting
  • Metastatic Breast Cancer
  • Hospitalet de Llobregat, Barcelona, Spain
  • +6 more
Jan 23, 2023

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Houston

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Anti-TGF-beta Monoclonal Antibody SAR-439459
  • Cemiplimab
  • Houston, Texas
    M D Anderson Cancer Center
Feb 9, 2022

Health Care Interventions and Outcomes of Major Bleedings in

Not yet recruiting
  • Major Bleeding
  • None (Observational study)
  • (no location specified)
Nov 17, 2023

Anemia in Dialysis-dependent CKD Patients Trial in Alexandria (Roxadustat)

Recruiting
  • Anemia in Dialysis-dependent CKD Patients
  • Alexandria, Egypt
    Alexandria University
Oct 29, 2023

25OH Vitamin D Overdoses and Risk of Bronchopulmonary Dysplasia

Recruiting
  • Bronchopulmonary Dysplasia
  • Vitamin D Overdose
  • Is 25 OH vitamin D overdose a risk factor of bronchopulmonary dysplasia or death ?
  • Bron, France
    Hôpital Femme Mère Enfant
Jul 13, 2023

Development and Malignant Transformation of Oral Lichen Planus

Completed
  • Oral Lichen Planus
  • Vitamin D Deficiency
  • ELISA
  • Fayoum, Egypt
    Fayoum University
Sep 8, 2023

Atrial Fibrillation, Anticoagulant-induced Bleeding Trial in Seoul (Factor Xa Inhibitor)

Recruiting
  • Atrial Fibrillation
  • Anticoagulant-induced Bleeding
  • Factor Xa Inhibitor
  • Seoul, Jongno-gu, Korea, Republic of
    Seoul National university Hostpital
Apr 5, 2023

Dynamics of Anti-factor VIII Antibody Signature During Treatment

Not yet recruiting
  • Severe Hemophilia A
  • +2 more
  • no interventions
  • (no location specified)
Apr 4, 2023

Type 3 Von Willebrand International Registries Inhibitor

Active, not recruiting
Has Results
  • Type 3 Von Willebrand's Disease
  • Von Willebrand Factor
  • Helsinki, Finland
  • +24 more
Mar 21, 2022

A Prospective and Retrospective Interventional Study on

Recruiting
  • Severe Hemophilia A Without Inhibitor
  • serum biomarker.
  • Taipei, Neihu Dist., Taiwan
    Tri-Service General Hospital Hemophilia Care Center
Aug 10, 2023

Refractory Angina Pectoris, Gene Transfer, Coronary Artery Disease Trial in Copenhagen, Kuopio (AdvVEGF-D, Control Rx)

Recruiting
  • Refractory Angina Pectoris
  • +2 more
  • Copenhagen, Denmark
  • +1 more
Oct 19, 2022

AORTIC VALVE DISEASES, Thromboembolism Trial in Korea, Republic of (Rivaroxaban Oral Tablet, Vitamin K antagonist(warfarin))

Recruiting
  • AORTIC VALVE DISEASES
  • Thromboembolism
  • Rivaroxaban Oral Tablet
  • Vitamin K antagonist(warfarin)
  • Bucheon, Korea, Republic of
  • +8 more
Oct 11, 2022

Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate

Not yet recruiting
  • Cancer of Cervix
  • Apoptosis
  • Immunohistochemistry
  • (no location specified)
Nov 17, 2023

Multiple Myeloma Trial (Bone marow biopsy and aspiration, biochemical and heamatological tests)

Not yet recruiting
  • Multiple Myeloma
  • Bone marow biopsy and aspiration
  • biochemical and heamatological tests
  • (no location specified)
Aug 9, 2023

Coagulation Disorder Trial (PROTHROMPLEX TOTAL, 4F-PCC)

Not yet recruiting
  • Coagulation Disorder
  • (no location specified)
Jul 14, 2022

Severe Hemophilia A Without Inhibitor, Joint Bleed Trial in Bangkok ("Emicizumab", "HEMLIBRA®")

Recruiting
  • Severe Hemophilia A Without Inhibitor
  • Joint Bleed
  • "Emicizumab", "HEMLIBRA®"
  • Bangkok, Thailand
    King Chulalongkorn Memorial hospital
Nov 25, 2023

Menstrual Bleeding, Heavy Trial in Portland (Sample Collection and Endometrial Biopsy)

Not yet recruiting
  • Menstrual Bleeding, Heavy
  • Sample Collection and Endometrial Biopsy
  • Portland, Oregon
    OHSU
May 8, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Drug Resistant Epilepsy Trial in Medan (Cholecalciferol, )

Not yet recruiting
  • Drug Resistant Epilepsy
  • Medan, North Sumatra, Indonesia
    Faculty of Medicine Universitas Sumatera Utara
Sep 21, 2023

Urgent Surgery Trial (Andexanet alfa, Usual Care)

Not yet recruiting
  • Urgent Surgery
  • Andexanet alfa
  • Usual Care
  • (no location specified)
Jun 21, 2023

Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • combination therapy with no MEKi
  • +3 more
  • (no location specified)
Nov 29, 2022

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Advanced Non Small Cell Lung Cancer Trial in Changchun, Shanghai, Hangzhou (D-0316)

Active, not recruiting
  • Advanced Non Small Cell Lung Cancer
  • Changchun, Jilin, China
  • +2 more
Apr 29, 2022